共 50 条
- [31] Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trialLANCET ONCOLOGY, 2023, 24 (10): : 1134 - 1146Gao, XiangyuXu, NongLi, ZiyuShen, LinJi, KeZheng, ZhongLiu, DanLou, HanmeiBai, LiLiu, TianshuLi, YunxiaLi, YuzhiFan, QingxiaFeng, MeiZhong, HaijunHuang, YiLou, GeWang, JingLin, XiaoyanChen, YeAn, RuifangLi, ChangzhengZhou, QiHuang, XinGuo, ZengqingWang, ShubinLi, GuilingFei, JunweiZhu, LijingZhu, HongLi, XiuminLi, FenghuLiao, SihaiMin, QinghuaTang, LeiShan, FeiGong, JifangGao, YunongZhou, JunLu, ZhihaoLi, XiaofanLi, JianjieRen, HuiLiu, XiaohongYang, HongxiaLi, WentingSong, WeifengWang, Zhongmin MaxwellLi, BaiyongXia, Michelle
- [32] A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Coward, JermaineBen MarkmanNagrial, AdnanAbed, AfafWalpole, Imogen
- [33] DOSE ESCALATION OF NEXT GENERATION ANTI-CTLA-4 ANTIBODY ONC-392 IN COMBINATION WITH FIXED DOSE OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A622 - A622Hu-Lieskovan, SiwenHe, KaiTang, MeiChen, DanLiu, YangZheng, PanLi, Tianhong
- [34] Preclinical investigations and a first-in-human phase 1a trial of JS']JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumorsEXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)Zhou, ChenfeiJiang, JinlingXiang, XiaojunLiu, HongliWu, GuowuZeng, RuichaoLu, TongZhang, MengqiShen, YutengHong, MinZhang, Jun
- [35] DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY STUDY IN ADVANCED MULTIPLE MYELOMA - AN OPEN-LABEL, DOSE ESCALATION FOLLOWED BY OPEN-LABEL EXTENSION IN A SINGLE-ARM PHASE I/II STUDYHAEMATOLOGICA, 2013, 98 : 241 - 241Lokhorst, H.Plesner, T.Gimsing, P.Nahi, H.Lisby, S.Richardson, P.
- [36] A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced MalignanciesCANCER, 2018, 124 (19) : 3890 - 3899Fountzilas, ChristosJavle, MilindTan, WeiMa, YingyuFetterly, GeraldIyer, RenukaJohnson, Candace
- [37] FIRST-IN-HUMAN PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: INITIAL PHASE 1 RESULTSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A239 - A239Friedman, ClaireAscierto, PaoloDavar, DiwakarO'Hara, MarkShapira-Frommer, RonnieDallos, MatthewKhemka, VivekJames, LeeFischer, BruceDemes, ShilpaLi, LiKozicki, MartinRavindran, PalanikumarXu, KeKollia, GeorgiaShoukry, JacquelineYunan, MonaMassey, AshishGutierrez, Martin
- [38] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trialINVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 473 - 482Zhu, XiaoxueDing, YanhuaWang, QianYang, GuiyuZhou, LiangWang, Qingyu
- [39] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trialInvestigational New Drugs, 2023, 41 : 473 - 482Xiaoxue ZhuYanhua DingQian WangGuiyu YangLiang ZhouQingyu Wang
- [40] Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Heery, Christopher RyanCoyne, Geraldine Helen O'SullivanMarte, Jennifer L.Singh, HarpreetCordes, Lisa M.Madan, Ravi AmritDonahue, Renee NicoleGrenga, ItaliaLepone, LaurenNeuteboom, BerendSpeit, IsabellChin, Kevin M.Schlom, JeffreyGulley, James L.